Successful treatment of vitamin D unresponsive hypoparathyroidism with multipulse subcutaneous infusion of teriparatide

European Journal of Endocrinology

Volumn 159, Issue 5, 2008, Pages 653-657

  Puig Domingo, Manel ^a   Díaz, Gonzalo ^a   Nicolau, Joanna ^a   Fernández, Cristián ^a   Rueda, Sergio ^a   Halperin, Irene ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; EVEROLIMUS; MAGNESIUM; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHATE; RECOMBINANT PARATHYROID HORMONE; THIAZIDE DIURETIC AGENT; VITAMIN D;

ADULT; ARTICLE; ASTHMA; BONE DENSITOMETRY; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GRAFT REJECTION; HUMAN; HYPERCALCIURIA; HYPERTHYROIDISM; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPARATHYROIDISM; INJECTION SITE PAIN; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; NODULAR GOITER; OSTEOPENIA; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID TRANSPLANTATION; PHOSPHATE BLOOD LEVEL; PREOPERATIVE CARE; PRIORITY JOURNAL; SIDE EFFECT; TACHYPHYLAXIS; THYROIDECTOMY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; DRUG RESISTANCE; FEMALE; HUMANS; HYPOCALCEMIA; HYPOPARATHYROIDISM; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; MIDDLE AGED; PARATHYROID GLANDS; PARATHYROID HORMONE; POSTOPERATIVE COMPLICATIONS; TERIPARATIDE; VITAMIN D;

EID: 56749158799     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0269     Document Type: Article

References (20)

1. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. New England Journal of Medicine 2000 343 1863-1875.
2. Torregrosa NM, Rodríguez JM, Llorente S, Balsalobre MD, Rios A, Jimeno L & Parrilla P. Definitive treatment for persistent hypoparathyroidism in a kidney transplant patient: parathyroid allotransplantation. Thyroid 2005 15 1299-1302.
3. Page C & Strunski V. Parathyroid risk in total thyroidectomy for bilateral, benign, multinodular goitre: report of 351 surgical cases. Journal of Laryngology and Otology 2007 121 237-241.
4. Winer KK, Ko CW, Reynolds JC, Dowdy K, Ked M, Peterson D, Gerber LH, McGarvey C & Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. Journal of Clinical Endocrinology and Metabolism 2003 88 4214-4220.
5. Winer KK, Yanovski JA, Sarani B & Cutler GB Jr. A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism 1998 83 3480-3486.
6. Winer KK, Yanovski JA & Cutler GB Jr. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism. Journal of the American Medical Association 1996 276 631-636.
7. Angelopoulos NG, Goula A & Tolis G. Sporadic hypoparathyroidism treated with teriparatide: a case report and literature review. Experimental and Clinical Endocrinology and Diabetes 2007 115 50-54.
8. Malloy PJ, Xu R, Peng L, Peleg S, Al-Ashwal A & Feldman D. Hereditary 1,25-dihydroxyvitamin D resistant rickets due to a mutation causing multiple defects in vitamin D receptor function. Endocrinology 2004 145 5106-5114.
9. Konrad M & Weber S. Recent advances in molecular genetics of hereditary magnesium-losing disorders. Journal of the American Society of Nephrology 2003 14 249-260.
10. Schaefer F. Pulsatile parathyroid hormone secretion in health and disease. Novartis Foundation Symposium 2000 227 225-239.
11. Harms HM, Kaptaina U, Klpmann WR, Brabant G & Hesch RD. Pulse amplitude and frequency modulation of parathyroid hormone in plasma. Journal of Clinical Endocrinology and Metabolism 1989 69 843-851.
12. Farooki A, Fornier M & Girotra M. Anabolic therapies for osteoporosis. New England Journal of Medicine 2007 357 2410-2411.
13. Davies M. High-dose vitamin D therapy: indications, benefits and hazards. International Journal for Vitamin and Nutrition Research 1989 30 81-86.
14. Shiohara M, Shiozawa R, Kurata K, Matsuura H, Arai F, Yasuda T & Koike K. Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor. Endocrine Journal 2006 53 797-802.
15. Kang JH, Choi HJ, Cho HY. Lee JH, Ha IS, Cheong HI & Choi Y. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis associated with CLDN16 mutations. Pediatric Nephrology 2005 20 1490-1493.
16. Nawrot I. Woźniewicz B, Tolloczko T, Sawicki A, Górski A, Chudziński W, Wojtaszek M, Grzesiuk W. Sladowski D, Karwacki J, Zawitkowska T & Szmidt J. Allotransplantation of cultured parathyroid progenitor cells without immunosuppression: clinical results. Transplantation 2007 27 734-740.
17. Liu X, Pettway GJ, McCauley LK & Ma PX. Pulsatile release of parathyroid hormone from an implantable delivery system. Biomaterials 2007 28 4124-4131.
18. Sato M, Ma YL, Hock JM, Westmore MS, Vahle J, Villanueva A & Turner CH. Skeletal efficacy with parathyroid hormone in rats was not entirely beneficial with long-term treatment. Journal of Pharmacological and Experimental Therapeutics 2002 302 304-313.
19. Poole KE & Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Current Opinion in Pharmacology 2005 5 612-617.
20. Lotinun S, Sibonga JD & Turner RT. Differential effects of intermittent and continuous administration of parathyroid hormone on bone histomorphometry and gene expression. Endocrine 2002 17 29-36.